comparemela.com

Latest Breaking News On - Bio pharma inc - Page 9 : comparemela.com

BridgeBio Pharma and Kyowa Kirin Announce Partnership with

- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive.

Japan
United-states
Tokyo
America
Neil-kumar
Asia-pacific
Yasuo-fujii
Vikram-bali
Bridgebio-pharma-inc
Nasdaq
Head-of-strategy-division-at-kyowa-kirin
Securities-exchange

Blueshift Asset Management LLC Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Blueshift Asset Management LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,482 shares of the company’s stock, valued at approximately $435,000. Several other large investors have also recently made changes to […]

Bridgebio-pharma
Bio-pharma
Frank-mccormick
Hannah-valantine
Emerald-advisers
Moody-aldrich-partners
Wells-fargo-company
Bio-pharma-inc
Nasdaq
Emerald-mutual-fund-advisers
Citigroup
Bridgebio-pharma-inc

AstraZeneca celebrates latest successful trial of acoramidis in Japan

AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan. The Cambridge,.

London
City-of
United-kingdom
Japan
Cambridge
Cambridgeshire
Astrazeneca-alexion
Emma-curzon
Mark-dunoyer
Bio-pharma-inc
Astrazeneca
Alliance-news-ltd

AstraZeneca (AZN) reports positive high-level results from Japan Phase III trial of acoramidis

AstraZeneca (AZN) reports positive high-level results from Japan Phase III trial of acoramidis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
Nagasaki
Yamagata
Marc-dunoyer
Yukio-ando
Bio-pharma-inc
Nasdaq
Nagasaki-international-university
Department-of-amyloidosis-research
Eidos-therapeutics-inc
Japan-phase
Bridgebio-pharma

Japan Phase III Trial Finds Acoramidis Effective for ATTR-CM

Japan Phase III Trial Finds Acoramidis Effective for ATTR-CM
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Nagasaki
Yamagata
Japan
Yukio-ando
Marc-dunoyer
Department-of-amyloidosis-research
Eidos-therapeutics-inc
Nagasaki-international-university
Bio-pharma-inc
Japan-phase
Bridgebio-pharma
Astrazeneca-rare-disease
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.